Tools chosen: kalshi_direct kalshi_related polymarket_related claude_news gdelt_news congress_bills wikipedia code_execution

Sub-questions (Fermi decomposition)

Planner reasoning

This is a long-horizon Kalshi policy question about whether Trump takes an action eliminating the cost of at least one IVF cycle before Jan 20, 2029. Key drivers: the Feb 2025 executive order on IVF access, the Oct 2025 White House announcement on TrumpRx/EMD Serono fertility drug pricing and employer 'fertility benefit' guidance, whether any of these actually zero out an IVF cycle's cost, and whether legislation or CMS/HHS rulemaking could mandate full coverage. I'll anchor on the Kalshi price and gather policy news plus legislative status.

# Current state Kalshi YES price is 13% as of latest data. No federal action to date has eliminated the cost of even one IVF cycle; the Feb 2025 EO set policy direction only, and the Oct 2025 TrumpRx/EMD Serono deal cuts drug costs (up to 84% off drugs) but leaves ~$15-20K in non-drug IVF costs (monitoring, retrieval, lab, transfer) unpaid, and explicitly excludes Medicaid/Medicare/TRICARE/VA beneficiaries. Resolution requires a full IVF cycle to become cost-free, which has not happened. # Timeline of key events - 2025-02: Trump signs EO 14216 "Expanding Access to In Vitro Fertilization," directing agencies to recommend ways to reduce IVF costs; no binding mandate created (confirmed, govinfo.gov). - 2025-05 (90-day deadline): Administration misses self-imposed deadline to release IVF cost-reduction recommendations; no findings released (confirmed, NBC News). - 2025-06 to 2025-07: Multiple Democratic-sponsored Senate bills introduced (Protect IVF Act, Access to Fertility Treatment and Care Act, Veteran Families Health Services Act) — all referred to committee, none advanced (confirmed, congress.gov). - 2025-10-16: White House/TrumpRx announces EMD Serono deal cutting prices on 3 IVF drugs (Gonal-F, Ovidrel, Cetrotide) by 70-84%; officials concede this "falls short" of the free-IVF pledge (confirmed, CNN/Businesswire/HealthDay). - ~2025 (undated): DOL/HHS/Treasury issue joint guidance allowing employers to voluntarily offer fertility benefits as "excepted benefits"; not a mandate (confirmed, ASRM). - 2025-11-12: NDAA (S.2296) held at desk; reports indicate Speaker Johnson stripped TRICARE fertility coverage expansion from the bill, blocking a military IVF benefit (reported, ASRM statement). - 2026-02-05: TrumpRx platform officially launches; hard exclusion for Medicaid/Medicare/TRICARE/VA beneficiaries confirmed (confirmed, Congress.gov CRS / ivfpharmacy.com). - 2026-06 to 07: New Democratic bills (Right to IVF Act of 2026, Let Doctors Provide Reproductive Health Care Act) introduced/referred to committee; no floor action (confirmed, congress.gov). # Event Will Trump take an action that eliminates the cost of at least one full IVF cycle before Jan 20, 2029 (KXFREEIVF-29)? # Outcomes to forecast Yes / No # Kalshi market anchor Current YES price: **13%**. 7-day change: 0%; 30-day change: -1%. Range over 118 days: 10%-18%. Average daily volume: ~56 contracts (thin market). Price has drifted down slightly and stabilized in low-teens, suggesting market has priced in that the Oct 2025 drug-discount deal does NOT satisfy resolution. # Sub-question answers 1. **Kalshi price/history** — 13% currently, been range-bound 10-18% over ~4 months of trading; low volume (~56/day) implies limited price discovery (Kalshi direct). 2. **Concrete actions taken** — Feb 2025 EO 14216 (policy direction only), Oct 2025 TrumpRx/EMD Serono drug discount deal (70-84% off drugs only, not full cycle), voluntary DOL/HHS/Treasury employer fertility-benefit guidance (opt-in, not mandate). None eliminates full IVF cycle cost; officials admit the drug deal "falls short" (claude_news, CNN, ASRM). 3. **Pending legislation/rulemaking** — Multiple Democratic bills (Right to IVF Act 2026, Protect IVF Act, Veteran Families Health Services Act, Access to Fertility Treatment and Care Act) all stuck in committee with no GOP administration backing; a proposed DOL/HHS/Treasury rulemaking to expand fertility-benefit pathways is intended but not yet issued and remains voluntary in nature (congress_bills, ASRM). 4. **Administration future plans** — No specific administration commitment to fully mandate free IVF; NDAA attempt to expand TRICARE fertility coverage was reportedly blocked by Speaker Johnson, indicating internal GOP resistance even to narrower military benefit (ASRM/Newsweek). 5. **Obstacles** — ERISA/insurance-market structure limits federal mandate power over private plans; budget cost of full IVF mandate; religious-conservative wing of GOP opposes government-funded IVF (embryo-related objections); Congress narrowly divided, no floor votes on IVF bills (code_execution analysis, general context). 6. **Base rate** — No specific base-rate data provided, but analogous costly campaign healthcare promises (e.g., full drug price caps, universal coverage promises) historically see partial/incremental implementation rather than full delivery within one term (inferred, no direct precedent cited). 7. **Cross-market pricing** — No Polymarket markets exist on this topic (0 matches). Other Kalshi Trump-promise markets (manufacturing revival 14.4%, govt cuts $250B 7.1%) show similarly low probabilities for ambitious campaign pledges, consistent with skepticism toward big Trump promises being fully realized (kalshi_related). # Key facts (high-confidence, factual) 1. [govinfo.gov] EO 14216 (Feb 2025) directs cost-reduction recommendations but creates no mandate. 2. [CNN/Businesswire] Oct 16, 2025 TrumpRx deal cuts 3 IVF drug prices 70-84%; drugs are only part of ~$20K+ total IVF cost. 3. [CRS/ivfpharmacy.com] TrumpRx excludes Medicaid/Medicare/TRICARE/VA beneficiaries. 4. [ASRM] DOL/HHS/Treasury guidance on fertility benefits is voluntary/opt-in. 5. [ASRM/Newsweek] TRICARE fertility expansion was stripped from NDAA, not enacted. 6. [congress.gov] All IVF-related bills in 119th Congress remain in committee, none passed. # Cross-market signals - Kalshi related: Similar Trump campaign-promise markets (manufacturing 14.4%, gov't cuts 7.1%) also price low, suggesting systematic skepticism of ambitious Trump pledges being fulfilled. - Polymarket: No matching markets exist. - Sportsbook implied: N/A. # Analyst opinions and speculation - KFF: October plan's impact "limited" to employer opt-ins and drug discounts; doesn't achieve free IVF (KFF). - ASRM: Raises "emerging questions" about implementation feasibility and coverage gaps. - code_execution model: Scenario-weighted fair value ~14% (close to market's 13%), driven primarily by uncertainty over whether a narrow military/VA/federal-employee program would count as satisfying resolution — this is the single biggest swing factor (7.5%-24% range). # Directional lean per outcome - **Yes**: EO 14216 shows administration intent; a narrow executive/DoD/OPM action (e.g., free IVF for military/veterans/federal employees) remains plausible route with lower political/legal barriers; 3+ years remain until close. - **No**: All actions to date fall explicitly short per officials/reporters; ERISA/insurance structure blocks broad mandates; NDAA attempt to expand TRICARE was already blocked; GOP religious-conservative resistance; no legislation near passage; TrumpRx explicitly excludes federal beneficiaries who'd be easiest target for "free cycle." # Gaps / unknowns - Unclear how Kalshi will interpret "eliminates the cost of at least one IVF cycle" — narrow military/VA program ambiguity is the dominant uncertainty. - No visibility into unannounced future EOs/rulemaking in remaining term. - GDELT news tool failed (timeouts), limiting most-recent-news coverage beyond compiled claude_news summary. # Calibration anchors - Kalshi current YES price: **13%** (anchor). - Model-implied fair value: ~14% (base case), range 8.5%-23% depending on "narrow program counts" assumption. - Comparable Trump-promise markets pricing 7-14% for other ambitious pledges (manufacturing revival, spending cuts) support similar low-probability calibration for "free IVF."

1. Both forecasters converge tightly around the 13-14% Kalshi anchor (10% and 14%) without meaningfully engaging the brief's own stated range of 8.5%-23% for the "narrow program counts" ambiguity — neither explores the upper tail scenario where a VA/military free-cycle program is announced AND counted as satisfying resolution, which the brief flags as "the single biggest swing factor." 2. Forecast 1 goes below market (10%) citing that resolution "likely demands a broad benefit," but this is an unsupported interpretive assumption not established in the brief's gaps/unknowns section, which explicitly says the ambiguity is unresolved — this creates unwarranted confidence in a stricter reading than the evidence supports. 3. Neither forecast addresses the base-rate/reference-class point in the brief that "analogous costly campaign healthcare promises... historically see partial/incremental implementation" more rigorously, nor do they weight the cross-market comparables (manufacturing revival 14.4%, gov't cuts 7.1%) as a distinct calibration check versus just restating the Kalshi price. 4. Both treat "3+ years remain" as a mild upside factor but neither considers that political incentives could shift closer to the 2028 election cycle, where an administration facing pressure to show a "win" on a signature campaign promise might rush a narrow, symbolic action (e.g., federal employees only) specifically timed for election messaging — this scenario-timing dynamic is unexamined. 5. The thin market volume (~56 contracts/day) is noted by both but neither treats this as a reason to give less weight to the Kalshi anchor itself; if price discovery is poor, the "anchor near 13-14%" reasoning is weaker than presented, yet both essentially confirm the market price rather than independently stress-testing it. 6. Neither forecast considers a downside tail scenario: increasing conservative/religious-right pushback against IVF entirely (given embryo-related objections mentioned in obstacles) could result in the administration abandoning even the modest drug-discount approach, which would reinforce No but isn't explicitly modeled as a distinct pathway strengthening the No case beyond current inertia.

12% (69% confidence)

Yes: 12% No: 88%

Every concrete action to date explicitly falls short of eliminating a full IVF cycle's cost: EO 14216 is directional only, the TrumpRx/EMD Serono deal covers drugs (~a fraction of a ~$20K cycle) and officials conceded it 'falls short,' tri-agency fertility guidance is voluntary, TrumpRx excludes federal beneficiaries, and the narrowest plausible path (TRICARE fertility expansion) was already stripped from the NDAA. All IVF bills sit in committee with no GOP backing, and ERISA/fiscal/religious-conservative constraints block a broad mandate. The critique fairly notes the unresolved 'does a narrow military/VA/federal-employee free-cycle program count?' ambiguity and the pre-2028 political incentive to manufacture a signature-promise 'win,' which justifies not sitting below market as Forecast 1 did. Balancing that upside tail against the strong structural No case and the thin market's weak price discovery, I land essentially at the 13% anchor, a shade lower at 12% given the repeated demonstrated failures of even the easiest pathways.

Total pipeline time: 176.8s